|
PAHO completes pilot project on malaria pharmacovigilance in Brazil
The Pan American Health Organization (PAHO) finished the pilot project “Strengthening Pharmacovigilance and Adherence to Malaria Treatment in the Region of the Americas (VigilADMa).” The country was the first to implement and complete the action, developed in the municipality of Manaus, state of Amazonas, from November 2019 to December 2020.
Read more
|
|
|
Latin American countries advance in the surveillance of antimicrobial consumption
PAHO, together with the Centro Universitario de Farmacología de Argentina (known in Spanish as CUFAR), PAHO/WHO Collaborating Center in Argentina, is collaborating with countries in the Region of the Americas to register the national consumption of antimicrobials in the countries, following the World Health Organization (WHO) methodology. The initiative seeks to train professionals from the countries in data collection and install a common methodology for conducting these studies in the Region.
Read more
|
|
|
Countries of the Region begin the development of national plans for pharmaceutical services based on primary health care
PAHO shared with the countries of the Region a model proposal for the development of national work plans to transform pharmaceutical services towards primary health care (PHC). The document provides guidance for the development of the main content sections of the plan and the priority aspects to be adopted or adapted to the context of the country. Among the lines contemplated in the plan is the strengthening of the enforcement procedures of prescription sale of antimicrobials.
Read more
|
|
|
Global shortage of innovative antibiotics fuels emergence and spread of drug-resistance
The world is still failing to develop desperately needed antibacterial treatments, despite growing awareness of the urgent threat of antibiotic resistance, according to report by the World Health Organization. WHO reveals that none of the 43 antibiotics that are currently in clinical development sufficiently address the problem of drug resistance in the world’s most dangerous bacteria.
Read more
|
|
|
Diagnosis of new TB cases in the Americas reduced by 15-20% during 2020 due to the pandemic
The Americas, with 2.9%, and Europe, with 2.5%, are the regions with the lowest TB burden in the world. However, the COVID-19 pandemic has jeopardized the gains made in the fight to end the disease by 2050 globally. The active search for people who have had contact with someone with TB in order to provide them with preventive treatment is also part of the strategy recommended by PAHO/WHO. Ensuring the full implementation of these measures will substantially reduce not only transmission of infection and disease, but also development of drug resistance. Peru and Brazil account for 52% of all multi-drug-resistant TB cases on the continent.
Read more
|
|
|
WHO launches a digital version of its Model list of Essential Medicines (EML)
The World Health Organization has launched a new easy-to-access, digital version of its Model list of Essential Medicines (EML). The move will revolutionize the way this core WHO reference tool is used. More than 150 countries currently use the WHO list to work out which medicines best meet their national health contexts and priorities, so they can compile their own national essential medicines lists.
Read more
|
|
|
New WHO Guide to help countries expand access to essential medicines
WHO’s new user guide for countries, ‘Selection of medicines at country level’, is based on the WHO Model List of Essential Medicines. It sets out the key actions countries should undertake to develop and update their own national essential medicines lists based on the treatment needs of their populations and their capacity to reimburse payments for medicines.
Read more
|
|
|
The course on the implementation and strengthening of Programs for Optimizing Antimicrobials (PROA) in the Americas finishes
More than 320 managers, leaders and health professionals from Argentina, Brazil, Chile, Colombia, Costa Rica, Cuba, Ecuador, Guatemala, Mexico, Nicaragua, Panama, Peru and the Dominican Republic approved the course. They were trained to organize, implement and monitor the development of a PROA in their health institution and interpret the factors that influence behavior related to the prescription of antimicrobials.
Read more
|
|
|
Medical Product Alert N°2/2021: Falsified COVID-19 Vaccine BNT162b2
This WHO Medical Product Alert refers to falsified COVID-19 Vaccine identified as “BNT162b2” detected in Mexico in February 2021 and recently confirmed as falsified to the WHO. The falsified product was supplied and administered to patients outside authorized vaccination programs.
Read more
|
|
|
|
